Use of the medicine Alphagan®P in the treatment of paediatric glaucoma
- Authors: Katargina L.A.1, Mazanova E.V.1
-
Affiliations:
- The Helmholtz Moscow Research Institute of Eye Diseases
- Issue: Vol 9, No 3 (2014)
- Pages: 10-13
- Section: Articles
- URL: https://journals.rcsi.science/1993-1859/article/view/37588
- DOI: https://doi.org/10.17816/rpoj37588
- ID: 37588
Cite item
Full Text
Abstract
The article presents the experience of one of the modern anti-hypertensive medicine, approved for use in children, Alphagan® P in various forms, stages of congenital and secondary glaucoma in children. Data obtained in this study allowed us to estimate the effectiveness of the drug as monotherapy and in combined appointment, a comparative analysis of the degree of IOP reduction at different stages and forms of paediatric glaucoma, including young children.
Full Text
##article.viewOnOriginalSite##About the authors
Ljudmila Anatol'evna Katargina
The Helmholtz Moscow Research Institute of Eye Diseases
Email: katargina@igb.ru
д.м.н., профессор, заместитель директора по научной работе 105062, Moscow, Russia
Ekaterina Viktorovna Mazanova
The Helmholtz Moscow Research Institute of Eye Diseases
Email: dho@igb.ru
к.м.н., научный сотрудник отдела патологии глаз у детей 105062, Moscow, Russia
References
- Аветисов Э.С., Ковалевский Е.И., Хватова А.В. Руководство по детской офтальмологию. М.: Медицина; 1987.
- Moore W., Nischal K.K. Pharmacologic management of glaucoma in childhood. Paediatr. Drugs. 2007; 9(2): 71-9.
- Coppens G., Stalmans I., Zeyen T., Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J. Pediatr. Ophthalmol. Strabismus. 2009. 46(1): 12-8.
- Daubert G.P. Is brimonidine ophthalmic a safe therapy for infants? J. Clin. Pharmacol. Ther 2006; 31(3): 289-92.
- Montero-de-Espinosa I., Marquez-de-Aracena R., Morales C. Ocular hypertension in children treated with brimonidine 0,2%. A clinical study. Arch. Soc. Esp. Oftalmol. 2006; 81(3): 155-9.
- Bowman R.J., Cope J., Nischal K.K. Ocular and systemic side effects of brimonidine 0,2% eye drops (Alphagan) in children. Eye (Lond). 2004; 18(1): 24-6.